Company Overview and News

 
Fortress malls under siege as they lose appeal with investors

2018-04-12 theage.com.au
Under siege “fortress malls” will need to keep spending large sums on shopping centre upgrades to fend off the threat of online shopping, making them less appealing to investors over the long term, analysts say.

 
Fortress malls under siege as they lose appeal with investors

2018-04-12 smh.com.au
Under siege “fortress malls” will need to keep spending large sums on shopping centre upgrades to fend off the threat of online shopping, making them less appealing to investors over the long term, analysts say.

 
ASX inches higher ahead of US Fed interest rate decision

2018-03-21 theage.com.au
Australian shares edged higher with investors cautious as they waited for a US Federal Reserve decision on interest rates that is widely expected to see the Fed hike for the sixth time this cycle.

 
ASX inches higher ahead of US Fed interest rate decision

2018-03-21 smh.com.au
Australian shares edged higher with investors cautious as they waited for a US Federal Reserve decision on interest rates that is widely expected to see the Fed hike for the sixth time this cycle.

 
Global property market is entering the last stage of cycle, warns veteran investor

2018-02-28 scmp
Collin Lau, founder of Bei Capital, says it’s time to exercise caution and adopt an asset-light approach

 
State faces backlash over freeze on towers

2018-02-22 smh.com.au
The Victorian government failed to notify developers it will freeze $4.5 billion worth of apartment projects in Australia’s largest urban renewal precinct, sparking frustration and accusations it is presiding over a “policy pendulum.”

 
ASX runs out of puff ahead of US inflation data

2018-02-14 smh.com.au
The ASX fell on Wednesday, weighed down by a drop in CBA shares ahead of US inflation data that some traders believe will dictate the next move for markets.

 
S&P/ASX 200 finishes down 0.3% to 5,841, US inflation data tonight

2018-02-14 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) closed down 15 points lower or 0.3% to 5,841 points.

 
S&P/ASX 200 bounces off low and tries to rally into the close

2018-02-14 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) has started to rally off its low of 5,831 at around 1.45pm.

 
S&P/ASX 200 opens higher but gives back early gains

2018-02-14 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) opened higher this morning but has since given back its gains.

 
S&P/ASX 200 futures rise as Dow Jones records third straight day of gains

2018-02-13 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) will look to feed off another day of gains in the US markets overnight.

 
Five things to watch for this company earnings season

2018-02-04 theage.com.au
Earnings season kicks off this month, with shareholders keen to know how the nation's top companies are handling overseas competition and performing in lucrative new markets.

 
Five things to watch for this company earnings season

2018-02-04 smh.com.au
Earnings season kicks off this month, with shareholders keen to know how the nation's top companies are handling overseas competition and performing in lucrative new markets.

 
What to Watch For as Australia's Earnings Season Kicks Off - Bloomberg

2018-02-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Lane Cove home to new vertical industrial units

2017-11-28 theage.com.au
Vertical industrial properties are now in high demand across metropolitan Sydney to cater for the increase use of e-commerce and fulfilment of "last-mile delivery" promises.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...